|
Oral Rodent Tuber (Thyphonium flagelliforme) Consumption on Lung Cancer
|
|
| Author:
|
ASRIL BURHAN, ELLY WAHYUDIN, MUH HARUN ISKANDAR
|
| Abstract:
|
Introduction: Epidemiologic and preclinical data support the cancer prevention potential of rodent tuber
(Typonium Flagelliforme). We compared the overall outcome of patients who received a capsule extract of
rodent tuber (CeRT) and refused chemotherapy or taking antineoplastic therapy on lung carcinoma.
Method: We randomly assigned patients with lung carcinoma stage III-IV who refused chemotherapy to
receive CeRT 3.0 g a day for 90 days, evaluating symptoms (breathless, vomiting, nausea, chest pain, cough, and
anorexia) during therapy while tumour mass in baseline and after treatment using thorax multislice computed
tomography (MSCT) and analyzed base on the response evaluation criteria in solid tumors criteria (RECIST).
Result: In the CeRT patient (n= 10) showed a significant reduction in complication symptoms, i.e., breathless,
coughing, and chest pain than in the chemotherapy population (n= 10) significant reduction in 2 parameters
(breathless and chest pain). On the thorax MSCT parameter, the CeRT showed a few reduction of tomour
mass after treatment, while the chemotherapy illustrated a significant reduction of tumour mass after
treatment. Value: The analysed clinical trials by giving CeRT provided evidence to increase the quality of life
of lung cancer patients. Although CeRT is not as good as effect with chemotherapy effect in reducing the
tomour mass, CeRT can reduce the symptom and highly valued by cancer patients.
|
| Keyword:
|
Clinical outcome, Lung carcinoma, Refused chemotherapy, Rodent tuber
|
| EOI:
|
-
|
| DOI:
|
-
|
| Download:
|
Request For Article
|
|
|